1. Outcomes of haploidentical transplants with PT-CY vs 10/10 MUD transplants with ATG in Germany
- Author
-
Aysenur Arslan, Svenja Labuhn, Elisa Sala, Mark Ringhoffer, Johannes Schetelig, Thomas Schröder, Gesine Bug, Georg-Nikolaus Franke, Matthias Stelljes, Peter Dreger, Robert Zeiser, Daniel Teschner, Wolfgang Bethge, Matthias Eder, Matthias Edinger, Elisa Maria Amann, Christine Neuchel, Amelie Schmid-Möglich, Sandra Schmeller, Jan Beyersmann, Hubert Schrezenmeier, Joannis Mytilineos, Nicolaus Kröger, Daniel Fürst, Thomas Schroeder, Uwe Platzbecker, Ahmet Elmaagacli, Inken Hilgendorf, Andreas Burchert, Friedrich Stölzel, Mareike Verbeek, Johanna Tischer, Arne Brecht, Martin Kaufmann, Christoph Kimmich, Jörg Thomas Bittenbring, Gerald Wulf, Igor Wolfgang Blau, Julia Winkler, Edgar Jost, Tobias Holderried, Mareike Dürholt, Christof Scheid, Eva Wagner-Drouet, Denise Wolleschak, Michael Kiehl, Friederike Wortmann, Guido Kobbe, Roland Schroers, Angela Krackhardt, Stefan Klein, Lutz P. Müller, Christoph Schmid, Stephan Kaun, Ute Wieschermann, Tobias Bartscht, Ralf Georg Meyer, Matthias Wölfl, Peter Bader, Judith Niederland, Jakob Maucher, Christine Mauz-Körholz, Birgit Burkhardt, Karim Kentouche, Jakob Passweg, and Karoline Ehlert
- Subjects
Specialties of internal medicine ,RC581-951 - Abstract
Abstract: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the best curative treatment modality for many malignant hematologic disorders. In the absence of a matched related donor, matched unrelated donors (MUDs) and haploidentical donors are the most important stem cell sources. In this registry-based retrospective study, we compared the outcomes of allo-HSCTs from 10/10 MUDs with antithymocyte globulin (ATG)–based regimens (n = 7050) vs haploidentical transplants (Haplo-Tx) using posttransplant cyclophosphamide (PT-CY Haplo; n = 487) in adult patients with hematologic malignancies between 2010 and 2020. Cox proportional hazard-and competing risks regression models were formed to compare the outcomes. Overall survival (OS), Disease-free survival (DFS), and graft-versus-host disease (GVHD)–free and relapse-free survival (GRFS) were superior for 10/10 MUDs (OS [hazard ratio (HR), 1.27; 95% confidence interval (CI), 1.10-1.47; P = .001]; DFS [HR, 1.17; CI, 1.02-1.34; P = .022]; GRFS [HR, 1.34; CI, 1.19-1.50; P
- Published
- 2024
- Full Text
- View/download PDF